Sienna Biopharmaceuticals to Present at JMP Securities Life Science Conference

Author's Avatar
Jun 14, 2018
Article's Main Image

WESTLAKE VILLAGE, Calif., June 14, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (SNNA, Financial) today announced that Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to present at the JMP Securities Life Science Conference, Wednesday, June 20, 2018, 8 a.m. EDT, in New York.

The presentation will be webcast live and can be accessed through the Investor Relations section of the Company’s website at Investors.SiennaBio.com. An archived version of the webcast will be available approximately two hours following the live presentation for 90 days.

About Sienna Biopharmaceuticals

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. The Company’s objective is to develop an innovative, diversified, multi-asset pipeline of topical therapies that enhance the health, appearance and quality of life of dermatology and aesthetics patients. Sienna is led by a management team with extensive experience in product development and commercialization at several leading dermatology, aesthetics and biotechnology companies.

For more information, visit the Company’s website at www.SiennaBio.com.

Contact:

Sean Andrews (Investors)
[email protected]
818-629-2244

Crystal Muilenburg (Media)
[email protected]
818-584-1035

ti?nf=NzMwMzU0NyMyMzY0NDM5IzIwODU5NDc=